[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrial-fibrillation-ablation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrial-fibrillation-ablation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,76,103,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100642550","association-between-circulating-bdnf-levels-and-atrial-cardiomyopathy-in-patients-undergoing-ablation-for-persistent-atrial-fibrillation-100642550",false,"NCT07648329","Association Between Circulating BDNF Levels and Atrial Cardiomyopathy in Patients Undergoing Ablation for Persistent Atrial Fibrillation","METAPROFIL 2","Inclusion Criteria:\n\n* Participants who have provided written consent\n* Patients aged 18 years or older.\n* Patients scheduled to undergo their first ablation procedure for persistent atrial fibrillation at the Dijon Bourgogne University Hospital\n\nExclusion Criteria:\n\n* A person who is not enrolled in or eligible for a social security program\n* A person subject to a legal protective measure (guardianship, conservatorship)\n* Person subject to a judicial safeguard measure\n* Pregnant or breastfeeding woman\n* Adult who is legally incapacitated or unable to give consent\n* Ablation of paroxysmal AF with or without electroanatomical mapping","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","trial fibrillation (AF) is the most common cardiac arrhythmia worldwide, and its prevalence continues to rise. AF is associated with serious complications, including embolic strokes, heart failure, and mortality. Characterized by rapid, irregular, and weakened contractions of the atria, AF is considered one of the \"visible\" electrophysiological manifestations of a broader condition known as atrial cardiomyopathy (ACM). Disruption of normal blood flow in the atrium, particularly in the context of an endocardium predisposed to thrombosis, predisposes to thrombus formation. Once dislodged from the atrial cavity and migrating to the cerebral arteries, these thrombi can cause a cardioembolic stroke. The main risk factors for ACI\u002FAF are metabolic syndrome and aging. CMA is a condition that is difficult to diagnose because it is not clearly defined, except through histological analysis. Guided by the results of our experimental approaches, we aim to address this challenge by approaching CMA through one of its complications: persistent atrial fibrillation. Indeed, CMA can be assessed using electroanatomical mapping during atrial fibrillation ablation (AFA) procedures. During radiofrequency ablation of AF, electroanatomical mapping of the left atrium is performed to measure left atrial voltage, which serves as an indirect marker of the presence of atrial fibrosis, strongly associated with CMA. Other parameters relevant to the identification of CMA can be assessed during this procedure, such as conduction velocities and specific electrographic characteristics.\n\nWe plan to include 150 patients undergoing ablation for persistent atrial fibrillation at the Dijon Bourgogne University Hospital and to correlate circulating levels of BDNF (brain-derived neurotrophic factor) with electroanatomical mapping data of the left atrium. The electrical remodeling of the left atrium, including low-voltage areas and conduction velocity, as well as left atrial morphology assessed by pre-procedural cardiac computed tomography using the ADAS3 Galgo LA Module software, will be correlated with BDNF levels. Blood samples for BDNF assessment will be collected before or at the start of the ablation procedure, prior to any catheter insertion into the vessels.\n\nWhile investigating the association between BDNF levels and CMA characteristics during AF ablation, thereby confirming the pathophysiological relationship with atrial remodeling, our objective is also to evaluate the prognostic role of BDNF levels in clinical and rhythm outcomes following AF ablation. Thus, we will compare changes in BDNF levels after AF ablation at one-year follow-up, correlating them with the evolution of CMA-based on left atrial parameters assessed by echocardiography or cardiac computed tomography-autonomic nervous system balance and heart rhythm obtained via Holter monitoring, as well as clinical outcomes.",[24,25,26,27,28],"Atrial Fibrillation (AF)","Cardiac Arrhythmia","Atrial Fibrillation Ablation","BDNF","Atrial Cardiomyopathy","NOT_YET_RECRUITING","2026-06-10",{"date":32,"type":33},"2026-06-15","ACTUAL",{"date":35,"type":20},"2026-07",{"date":37,"type":20},"2029-07",{"name":39,"class":40},"Centre Hospitalier Universitaire Dijon","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":41},"100622315","tirzepatide-to-reduce-recurrence-and-burden-after-ablation-of-atrial-fibrillation-100622315","NCT07382024","Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation","Tirzepatide to Reduce Recurrence and Burden After Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Trial","TREAT-AF","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Diagnosed with persistent atrial fibrillation and scheduled for de novo catheter ablation.\n3. Body mass index (BMI) ≥27 kg\u002Fm² at screening accompanied by at least one weight-related comorbidity (including cardiovascular disease, hypertension, dyslipidemia, or prediabetes).\n4. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Long-standing AF or marked left atrial enlargement (persistent AF duration \\> 5 years or left atrial anterior-posterior diameter \\> 50 mm).\n2. AF secondary to reversible causes (e.g., hyperthyroidism, acute infection, acute pulmonary embolism, recent cardiac surgery).\n3. Severe structural heart disease that may significantly affect ablation outcomes (e.g., hypertrophic cardiomyopathy, rheumatic valvular disease, dilated cardiomyopathy).\n4. Planned major non-AF-related surgery or interventional procedure within 3 months.\n5. Other arrhythmias requiring chronic antiarrhythmic drug therapy.\n6. Intracardiac thrombus or any contraindication to catheter ablation as judged by the investigator.\n7. Active systemic infection at screening.\n8. Contraindications to tirzepatide or GLP-1\u002FGIP receptor agonists (e.g., prior serious hypersensitivity, personal or family history of medullary thyroid carcinoma or MEN2, history of clinically significant pancreatitis, severe gastrointestinal disease that may impair tolerance or absorption).\n9. Poorly controlled type 1 diabetes, recent diabetic ketoacidosis, end-stage renal disease requiring dialysis, or severe hepatic dysfunction judged clinically significant.\n10. Pregnancy, breastfeeding, or women of childbearing potential unwilling or unable to use adequate contraception during the study.\n11. Participation in another interventional clinical study within 30 days prior to screening or planned participation during the study period.\n12. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation, including inability to comply with study procedures or follow-up.","80 Years",{"count":52,"type":20},200,"INTERVENTIONAL",[55],"NA","The goal of this clinical trial is to determine whether tirzepatide can reduce atrial fibrillation (AF) burden after catheter ablation in overweight or obese patients with persistent AF. It will also evaluate the effects of tirzepatide on body weight, metabolic risk factors, and clinical outcomes, as well as its safety and tolerability in this population.\n\nThe main questions it aims to answer are:\n\n1. Does peri-procedural treatment with tirzepatide reduce AF burden at 3 months after de novo catheter ablation, as measured by 7-day continuous ECG patch monitoring?\n2. Does tirzepatide lead to greater weight loss and improvement in metabolic parameters compared with standard care alone?\n3. Does tirzepatide reduce AF recurrence and cardiovascular events during 12 months of follow-up? Researchers will conduct a multi-center, open-label, endpoint-blinded, randomized controlled trial in adults aged 18-80 years with persistent AF and body mass index ≥25 kg\u002Fm² who are scheduled for de novo catheter ablation. Participants will be randomized 1:1 to receive either tirzepatide plus standard peri-procedural and post-ablation care or standard care alone.\n\nParticipants in the tirzepatide group will receive subcutaneous tirzepatide 2.5 mg once weekly starting about 4 weeks before ablation and continuing for 3 months afterward, for a total treatment duration of approximately 4 months. All participants will be followed at 1, 2, 3, 6, and 12 months after ablation, with detailed assessment of AF burden, AF recurrence, echocardiographic parameters, metabolic profile, quality of life by the AFEQT questionnaire, and safety events.",[26,58,59],"Persistent Atrial Fibrillation","Obesity & Overweight",[61,62,63,64,65,66,67],"Atrial fibrillation","Catheter ablation","Tirzepatide","Overweight and obesity","AF burden","Recurrence","Quality of life",{"date":69,"type":33},"2026-06-12",{"date":71,"type":20},"2026-06-16",{"date":73,"type":20},"2028-07-31",{"name":75,"class":40},"National Taiwan University Hospital",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":53,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":41},"100639560","pulsed-field-ablation-outcomes-with-efficacy-and-randomization-in-atrial-fibrillation-power-af-100639560","NCT07601763","Pulsed Field Ablation Outcomes With Efficacy and Randomization in Atrial Fibrillation (POWER-AF)","Pulsed Field Ablation for Atrial Fibrillation Including Posterior Wall and Linear Ablation: A Randomized Controlled Trial of Safety and Efficacy (POWER-AF)","POWER-AF","Inclusion Criteria:\n\n1. Atrial fibrillation patients who will accept catheter ablation.\n2. Age ≥ 18.\n3. Be capable of understanding and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Have contraindications for catheter ablation (such as atrial thrombosis, decompensated heart failure, etc.)\n2. Have accepted catheter ablation before.\n3. Myocardial infarction, or any cardiac interventional\u002Fsurgery has been performed within 3 months.\n4. Had a stroke or transient ischemic attack within 6 months.\n5. Allergy to iodine contrast agents.\n6. Participate in clinical trials related to other drugs or devices.\n7. Pregnant women, lactating women, or women with plans to become pregnant shortly.\n8. Active stage of infection.\n9. Secondary atrial fibrillation, such as combined with rheumatic heart disease, hypertrophic cardiomyopathy, etc.\n10. Patients who do not agree to be enrolled or are unable to cooperate to complete the study",{"count":85,"type":20},1574,[55],"Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice. As of 2019, there were approximately 59.7 million patients with AF worldwide, including atrial flutter (AF). Atrial fibrillation can significantly increase the risks of stroke, thromboembolism and heart failure in patients, seriously affecting their quality of life.\n\nCatheter ablation is the main means for rhythm control in patients with atrial fibrillation. A large number of clinical studies have confirmed the effectiveness and safety of catheter ablation for atrial fibrillation. It is significantly superior to drug treatment in maintaining sinus rhythm and can significantly improve symptoms and quality of life.\n\nPulsed electric field ablation (PFA) is a novel ablation method that utilizes pulsed electric fields as energy. It uses multiple short-duration and high-voltage electrical pulses to release ablation energy, selectively causing myocardial cells to rupture and die. However, it has no obvious damaging effect on blood vessels, nerves, and tissues around the heart, such as the lungs, esophagus, and phrenic nerve.\n\nThis trial was designed based on the advantage of the characteristic that PFA does not damage the esophagus, confining the damage to the posterior half of the left atrium and the circumferential isthmus of the mitral valve. While improving the ablation success rate, it is possible to protect the function of the left atrium. This study aims to verify the superiority of the new rhythm control strategy in a large-scale population by launching a prospective randomized controlled trial.",[24,26,89,90,91],"Atrial Fibrillation Recurrent","Pulsed Field Ablation","Radiofrequency Catheter Ablation","RECRUITING","2026-05-24",{"date":95,"type":33},"2026-05-28",{"date":97,"type":33},"2025-04-16",{"date":99,"type":20},"2028-11-30",{"name":101,"class":102},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":53,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":41},"100602996","comparative-intra-procedural-evaluation-of-farapulse-and-farawave-nav-catheters-100602996","NCT07130773","Comparative Intra-procedural Evaluation of Farapulse and FARAWAVE Nav Catheters","Procedural Comparative Evaluation of Pulmonary Vein Isolation Using the FARAWAVE Nav PFA Catheter Without Pre-Ablation Computer Tomography (CT) vs. Conventional Farapulse With Pre-Ablation CT: A Single Centre Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n* Atrial fibrillation (AF) documented on a 12-lead ECG, Holter monitor, or implantable cardiac device.\n* Candidate for ablation according to current atrial fibrillation guidelines.\n* Age ≥18 years at the time of informed consent.\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Previous left atrial ablation or left atrial surgery.\n* Presence of intracardiac thrombus.\n* Persistent atrial fibrillation lasting \\>3 years.\n* Severe mitral regurgitation or moderate-to-severe mitral stenosis.\n* Pregnancy (all women under 50 years undergo an HCG blood test prior to inclusion to exclude pregnancy).",{"count":111,"type":20},58,[55],"The FARAPULSE PFA catheter (Boston Scientific), a first-generation Pulsed Field Ablation (PFA) tool, has demonstrated good performance in isolating pulmonary veins (PV). Several centers, including ours, utilize pre-procedural computer tomography (CT) to evaluate individual pulmonary vein anatomy and optimize ablation planning. However, these imaging modalities are costly. Additionally, CT imaging exposes patients to radiation, and introduce significant logistical challenges to the procedural workflow.\n\nThe FARAWAVE Nav PFA catheter, a second-generation device, integrates magnetic navigation capabilities with detailed mapping and PFA therapy into a single tool. This system leverages the FARAVIEW Software Module, offering tailored mapping solutions visualized on the FARAPULSE PFA system, including the creation of voltage and activation maps.\n\nThese features address the limitations of the first-generation FARAPULSE catheter and have the potential to improve procedural accuracy and the durability of pulmonary vein isolation. Moreover, they may obviate the need for pre-procedural CT, thereby reducing costs and minimizing patient radiation exposure.\n\nOur study evaluates whether the FARAWAVE Nav catheter, used without pre-ablation CT, allows for a reduction in fluoroscopy time and overall patient radiation exposure compared to the conventional workflow with the FARAPULSE catheter. Furthermore, we will assess procedural time, costs, number of PFA applications, and AF recurrence-free survival",[24,26,90],[116,117,118,119,120,121,122,123],"pulsed filed ablation","atrial fibrillation","ablation","pulmonary vein isolation","electroanatomical map","ionizing radiation","farapulse","farawave nav","2026-03-17",{"date":126,"type":33},"2026-03-19",{"date":128,"type":33},"2025-11-10",{"date":130,"type":20},"2026-12",{"name":132,"class":40},"Cardiocentro Ticino",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":53,"phases":144,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":41},"100625596","catheter-ablation-vs-conservative-care-in-elderly-patients-with-atrial-fibrillation-100625596","NCT07424690","Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation","Assessment of the Effect of Catheter Ablation on Elderly Population With Atrial Fibrillation; a Randomized Controlled Study; The ACE-AF Study","ACE-AF","Inclusion Criteria:\n\n1. Age ≥78 years.\n2. ECG-documented atrial fibrillation.\n3. AF type: paroxysmal, persistent, or longstanding persistent AF.\n4. Suitable candidate for catheter ablation according to ESC guidelines.\n5. Charlson's comorbidity index ≤7.\n\nExclusion Criteria:\n\n1. Left atrial (LA) dimension \\>55 mm, based on echocardiography within the previous year.\n2. Acute coronary syndrome or coronary artery bypass surgery within the last 12 weeks.\n3. Severe valvular heart disease (per ESC definitions) or congenital heart disease.\n4. Prior surgical or catheter AF ablation procedure, or prior AV-node (atrioventricular nodal) ablation.\n5. Contraindication to oral anticoagulation.\n6. AF due to a reversible cause.\n7. Medical condition likely to limit survival to \\\u003C12 months.\n8. Unable or unwilling to provide informed consent.\n9. History of non-compliance with medical therapy.\n10. BMI \\\u003C18 or \\>37 kg\u002Fm².","78 Years",{"count":143,"type":20},282,[55],"ACE-AF is a multicenter randomized study in people aged 78 years and older with symptomatic atrial fibrillation (AF). AF is a common heart rhythm disorder in older adults and can cause reduced quality of life and lead to serious complications such as stroke and heart failure.\n\nThe study compares two established treatment strategies:\n\n1. Catheter ablation (an invasive procedure aimed at reducing AF by electrically isolating triggers in the heart, primarily through pulmonary vein isolation), and\n2. Optimized medical therapy without AF ablation (medications for rate and\u002For rhythm control; AV node ablation with pacemaker may be used if clinically indicated according to routine care).\n\nParticipants are randomized 1:1 to one of these strategies. All participants will receive an implantable loop recorder (a small heart rhythm monitor placed under the skin) to continuously track heart rhythm and measure AF burden over time.\n\nThe study has two co-primary outcomes assessed over 24 months:\n\n1. a composite of major clinical events (all-cause mortality, stroke, major bleeding, cardiac arrest, or hospitalization due to heart failure), and\n2. patient-reported health-related quality of life (HRQoL), measured by the SF-36 \"General Health\" domain.\n\nACE-AF will provide evidence to guide treatment decisions for very elderly patients with symptomatic AF and help identify which patients benefit most from an ablation-based strategy compared with optimized medical therapy.",[24,26,147],"Elderly",[117,149,150,151,152,153,154,155],"catheter ablation","rhtyhm control","rate control","implantable loop recorder","elderly","Health-related quality of life","Randomized controlled study","2026-02-14",{"date":158,"type":33},"2026-02-20",{"date":160,"type":20},"2026-05-20",{"date":162,"type":20},"2034-09-01",{"name":164,"class":40},"Karolinska University Hospital"]